This most comprehensive molecular-genetic test includes the complete mutational analysis of all human genes that code proteins (exome sequencing) and the activity analysis of the tumor’s entire circa 20.000 genes.

Using isolated, living tumor cells, this test determines the response to cytotoxic and biopharmaceutical treatments.

This molecular-genetic test serves to determine the risk of metastasis of both lymph node positive and lymph node negative primary breast cancer. It can thus be used to decide for or against adjuvant chemotherapy.

MultiOncogen Mutation tests are several, comprehensive mutational tests. When tailored to a specific tumor disease, MOMs identify the mutations relevant to target therapies.

The most comprehensive of the molecular-genetic tests determines the activity of all of a tumor’s genes. It thus allows evaluating the risk of primary breast cancer (OncoAssay Score) and the response to several possible courses of treatment. Suitable for all kinds of tumors.

The test is used to assess the risk of further growth of lymph node negative primary breast cancer. As such, it can be used to help make a decision for or against adjuvant chemotherapy.

The test identifies mutations in a tumor’s DNA via serum or plasma. It is used within the real-time mutation analysis in several tumor diseases under targeted therapy (real-time liquid biopsy). It allows for a timely discovery of a tumor’s growing resistance to the targeted therapy.

The test serves to determine how the blood is affected by tumor cells. It allows for a molecular-genetic characterization of the tumor disease (real-time liquid biopsy).

NextGen Oncology Group